Renin, angiotensin II and III in acute renal failure: note on the measurement of of angiotensin II and III in rat blood. 1976

P F Semple, and J J Brown, and A F Lever, and J MacGregor, and J J Morton, and J D Powell-Jackson, and J I Robertson

UI MeSH Term Description Entries
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D012082 Renal Veins Short thick veins which return blood from the kidneys to the vena cava. Renal Vein,Vein, Renal,Veins, Renal
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001806 Blood Urea Nitrogen The urea concentration of the blood stated in terms of nitrogen content. Serum (plasma) urea nitrogen is approximately 12% higher than blood urea nitrogen concentration because of the greater protein content of red blood cells. Increases in blood or serum urea nitrogen are referred to as azotemia and may have prerenal, renal, or postrenal causes. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984) BUN,Nitrogen, Blood Urea,Urea Nitrogen, Blood
D005990 Glycerol A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. It is used as a solvent, emollient, pharmaceutical agent, or sweetening agent. 1,2,3-Propanetriol,Glycerin,1,2,3-Trihydroxypropane,Glycerine
D006400 Hematocrit The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value. Erythrocyte Volume, Packed,Packed Red-Cell Volume,Erythrocyte Volumes, Packed,Hematocrits,Packed Erythrocyte Volume,Packed Erythrocyte Volumes,Packed Red Cell Volume,Packed Red-Cell Volumes,Red-Cell Volume, Packed,Red-Cell Volumes, Packed,Volume, Packed Erythrocyte,Volume, Packed Red-Cell,Volumes, Packed Erythrocyte,Volumes, Packed Red-Cell
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000805 Angiotensin III A heptapeptide formed from ANGIOTENSIN II after the removal of an amino acid at the N-terminal by AMINOPEPTIDASE A. Angiotensin III has the same efficacy as ANGIOTENSIN II in promoting ALDOSTERONE secretion and modifying renal blood flow, but less vasopressor activity (about 40%). Des-Asp Angiotensin II,Des-Aspartyl-Angiotensin II,Angiotensin II, Des-Asp,Des Asp Angiotensin II,Des Aspartyl Angiotensin II
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001011 Aorta The main trunk of the systemic arteries. Aortas

Related Publications

P F Semple, and J J Brown, and A F Lever, and J MacGregor, and J J Morton, and J D Powell-Jackson, and J I Robertson
August 1977, Lancet (London, England),
P F Semple, and J J Brown, and A F Lever, and J MacGregor, and J J Morton, and J D Powell-Jackson, and J I Robertson
December 1971, Laboratory investigation; a journal of technical methods and pathology,
P F Semple, and J J Brown, and A F Lever, and J MacGregor, and J J Morton, and J D Powell-Jackson, and J I Robertson
May 1967, Saishin igaku. Modern medicine,
P F Semple, and J J Brown, and A F Lever, and J MacGregor, and J J Morton, and J D Powell-Jackson, and J I Robertson
May 1967, Saishin igaku. Modern medicine,
P F Semple, and J J Brown, and A F Lever, and J MacGregor, and J J Morton, and J D Powell-Jackson, and J I Robertson
May 1967, Saishin igaku. Modern medicine,
P F Semple, and J J Brown, and A F Lever, and J MacGregor, and J J Morton, and J D Powell-Jackson, and J I Robertson
May 1967, Saishin igaku. Modern medicine,
P F Semple, and J J Brown, and A F Lever, and J MacGregor, and J J Morton, and J D Powell-Jackson, and J I Robertson
December 1976, The Johns Hopkins medical journal,
P F Semple, and J J Brown, and A F Lever, and J MacGregor, and J J Morton, and J D Powell-Jackson, and J I Robertson
January 1975, Clinical nephrology,
P F Semple, and J J Brown, and A F Lever, and J MacGregor, and J J Morton, and J D Powell-Jackson, and J I Robertson
July 1972, Medicina,
P F Semple, and J J Brown, and A F Lever, and J MacGregor, and J J Morton, and J D Powell-Jackson, and J I Robertson
June 1976, Circulation research,
Copied contents to your clipboard!